{"title":"甲状腺激素治疗扩张型心肌病:是一个有希望的治疗选择吗?","authors":"Hala Mahfouz Badranz","doi":"10.33696/cardiology.2.019","DOIUrl":null,"url":null,"abstract":"Dilated cardiomyopathy (DCM) is chronic heart muscle disease characterized by progressive ventricular enlargement and contractile dysfunction involving either left or both ventricles [1,2]. It is considered one of the leading causes of heart failure with reduced ejection fraction (HFrEF) worldwide. The reported prevalence of DCM in Europe and North America is ~36 cases per 100,000 population, which is clearly lower in Eastern Asia (i.e., 14 cases per 100,000 in Japan), and might be higher in Africa and Latin [3].","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thyroid Hormones in Dilated Cardiomyopathy: Is It a Promising Therapeutic Option?\",\"authors\":\"Hala Mahfouz Badranz\",\"doi\":\"10.33696/cardiology.2.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dilated cardiomyopathy (DCM) is chronic heart muscle disease characterized by progressive ventricular enlargement and contractile dysfunction involving either left or both ventricles [1,2]. It is considered one of the leading causes of heart failure with reduced ejection fraction (HFrEF) worldwide. The reported prevalence of DCM in Europe and North America is ~36 cases per 100,000 population, which is clearly lower in Eastern Asia (i.e., 14 cases per 100,000 in Japan), and might be higher in Africa and Latin [3].\",\"PeriodicalId\":15510,\"journal\":{\"name\":\"Journal of Clinical Cardiology\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.33696/cardiology.2.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33696/cardiology.2.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Thyroid Hormones in Dilated Cardiomyopathy: Is It a Promising Therapeutic Option?
Dilated cardiomyopathy (DCM) is chronic heart muscle disease characterized by progressive ventricular enlargement and contractile dysfunction involving either left or both ventricles [1,2]. It is considered one of the leading causes of heart failure with reduced ejection fraction (HFrEF) worldwide. The reported prevalence of DCM in Europe and North America is ~36 cases per 100,000 population, which is clearly lower in Eastern Asia (i.e., 14 cases per 100,000 in Japan), and might be higher in Africa and Latin [3].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
